The clinical trial report, “Amyotrophic Lateral Sclerosis - Global Clinical Trials Review, 2026" provides an overview of Amyotrophic Lateral Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Amyotrophic Lateral Sclerosis
- Apr 21, 2026: Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in NfL
- Apr 16, 2026: Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
- Apr 16, 2026: Ab Science Provides an Update on Its Clinical Development Program.
- Apr 09, 2026: Coya Announces Publication Demonstrating Correlation Between Biomarker Data and Clinical Outcomes Supporting Mechanistic Rationale for COYA 302 in ALS
- Apr 06, 2026: NeuroSense Granted Brazilian Patent Covering PrimeC Composition
- Apr 01, 2026: NUZ-001 Preclinical Data Shows Multi-Pathway Protein Clearance Activity
- Mar 31, 2026: Prilenia and Ferrer enrol first participant in PREVAiLS Phase III trial
- Mar 31, 2026: Trethera Announces Massachusetts General Hospital Clinical Trial Collaboration to Evaluate TRE-515 in ALS Patients
- Mar 23, 2026: Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis
- Mar 19, 2026: Additional Phase 2 Data of AL-S’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS
- Mar 18, 2026: PrimeC New Data to Be Presented at AD/PD 2026 Conference
- Mar 16, 2026: JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
- Mar 09, 2026: Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
- Mar 09, 2026: Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
- Mar 09, 2026: PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
- Mar 05, 2026: Tanabe Pharma America to Highlight Research in ALS at 2026 MDA Clinical and Scientific Conference
- Mar 04, 2026: Transposon Therapeutics’ TPN-101 to Be Studied for Extending Healthy Aging Under ARPA-H Award for up to $22M
- Mar 01, 2026: Cureverse Selected for 'Global Cluster R&BD' National Project
- Feb 24, 2026: AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
- Feb 24, 2026: AB Science Announces the Identification of a Plasma Biomarker That Indicates the Activity of Masitinib in Treating ALS
- Feb 19, 2026: NeuroSense’s ALS drug improves survival in Phase IIb trial
- Feb 10, 2026: Coya Therapeutics To Host Webinar With Leading Medical Experts on ALS Drug Development, Patient Landscape, and Ongoing Clinical Trial
- Clinical Trial Profile Snapshots
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Source
- Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*
- Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*
- Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Amyotrophic Lateral Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Amyotrophic Lateral Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Mitsubishi Chemical Group Corp
- Biogen Inc
- ICON Plc
- Cytokinetics Inc
- Sanofi
- The Nucleus Network Pty Ltd
- Amylyx Pharmaceuticals Inc
- Denali Therapeutics Inc
- Thermo Fisher Scientific Inc
- IQVIA Holdings Inc
